84 related articles for article (PubMed ID: 525843)
1. [Value of ultrastructural morphology in the preparation of oncolysates of human malignant melanoma].
Noël P; Faucon M; Leftheriotis E; Fontanière B; Bailly C; Carcagne C; Groleas M; Rezvoy M
Ann Anat Pathol (Paris); 1979; 24(2):125-35. PubMed ID: 525843
[TBL] [Abstract][Full Text] [Related]
2. [Response in patients with melanoma to immunization using melanoma oncolysates of vaccine virus].
Doré JF; Portoukalian J; Berthier-Vergnes O; Jacubovich R; Genève J; Bailly M; Lefthériotis E; Weissbrod A; Mayer M
Bull Cancer; 1990; 77(9):881-91. PubMed ID: 2224160
[TBL] [Abstract][Full Text] [Related]
3. Induction of IgG antibodies directed to a M(r) 31,000 melanoma antigen in patients immunized with vaccinia virus melanoma oncolysates.
Berthier-Vergnes O; Portoukalian J; Lefthériotis E; Doré JF
Cancer Res; 1994 May; 54(9):2433-9. PubMed ID: 8162593
[TBL] [Abstract][Full Text] [Related]
4. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
[TBL] [Abstract][Full Text] [Related]
5. [The treatment of advanced malignant melanoma with vaccina oncolysates (author's transl)].
Wallack MK
Nouv Presse Med; 1979 May; 8(23):1919-21. PubMed ID: 223123
[TBL] [Abstract][Full Text] [Related]
6. Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses.
Cassel WA; Murray DR; Torbin AH; Olkowski ZL; Moore ME
Cancer; 1977 Aug; 40(2):672-9. PubMed ID: 196739
[TBL] [Abstract][Full Text] [Related]
7. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues.
Real FX; Houghton AN; Albino AP; Cordon-Cardo C; Melamed MR; Oettgen HF; Old LJ
Cancer Res; 1985 Sep; 45(9):4401-11. PubMed ID: 4028024
[TBL] [Abstract][Full Text] [Related]
8. Expression of melanoma-associated antigens in rapidly dividing human melanocytes in culture.
Herlyn M; Rodeck U; Mancianti M; Cardillo FM; Lang A; Ross AH; Jambrosic J; Koprowski H
Cancer Res; 1987 Jun; 47(12):3057-61. PubMed ID: 3034401
[TBL] [Abstract][Full Text] [Related]
9. Ultrastructural comparison between cultured and tumor cells of human malignant melanoma.
Foa C; Aubert C
Cancer Res; 1977 Nov; 37(11):3957-63. PubMed ID: 908035
[TBL] [Abstract][Full Text] [Related]
10. Biology of tumor progression in human melanocytes.
Herlyn M; Clark WH; Rodeck U; Mancianti ML; Jambrosic J; Koprowski H
Lab Invest; 1987 May; 56(5):461-74. PubMed ID: 3553733
[TBL] [Abstract][Full Text] [Related]
11. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line.
Waanders GA; Rimoldi D; Liénard D; Carrel S; Lejeune F; Dietrich PY; Cerottini JC; Romero P
Clin Cancer Res; 1997 May; 3(5):685-96. PubMed ID: 9815737
[TBL] [Abstract][Full Text] [Related]
12. Human malignant melanoma. Melanosomal polymorphism and the ultrastructural dopa reaction.
Hunter JA; Paterson WD; Fairley DJ
Br J Dermatol; 1978 Apr; 98(4):381-90. PubMed ID: 638044
[TBL] [Abstract][Full Text] [Related]
13. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma.
Mittelman A; Chen GZ; Wong GY; Liu C; Hirai S; Ferrone S
Clin Cancer Res; 1995 Jul; 1(7):705-13. PubMed ID: 9816036
[TBL] [Abstract][Full Text] [Related]
14. Uveitis caused by cytotoxic immune response to cutaneous malignant melanoma in swine: destruction of uveal melanocytes during tumor regression.
Lentz KJ; Burns RP; Loeffler K; Feeney-Burns L; Berkelhammer J; Hook RR
Invest Ophthalmol Vis Sci; 1983 Aug; 24(8):1063-9. PubMed ID: 6874271
[TBL] [Abstract][Full Text] [Related]
15. Diffuse melanosis arising from metastatic melanoma: pathogenetic function of elevated melanocyte peptide growth factors.
Böhm M; Schiller M; Nashan D; Stadler R; Luger TA; Metze D
J Am Acad Dermatol; 2001 May; 44(5):747-54. PubMed ID: 11312419
[TBL] [Abstract][Full Text] [Related]
16. Phenotyping of lesions of melanocyte origin with monoclonal antibodies to melanoma-associated antigens and to HLA antigens.
Natali PG; Bigotti A; Cavaliere R; Nicotra MR; Ferrone S
J Natl Cancer Inst; 1984 Jul; 73(1):13-24. PubMed ID: 6376904
[TBL] [Abstract][Full Text] [Related]
17. HMB-45 antibody demonstrates melanosome specificity by immunoelectron microscopy.
Taatjes DJ; Arendash-Durand B; von Turkovich M; Trainer TD
Arch Pathol Lab Med; 1993 Mar; 117(3):264-8. PubMed ID: 8442672
[TBL] [Abstract][Full Text] [Related]
18. A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype.
Boukerche H; Baril P; Tabone E; Bérard F; Sanhadji K; Balme B; Wolf F; Perrot H; Thomas L
Cancer Res; 2000 Oct; 60(20):5848-56. PubMed ID: 11059782
[TBL] [Abstract][Full Text] [Related]
19. Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus.
Gnant MF; Berger AC; Huang J; Puhlmann M; Wu PC; Merino MJ; Bartlett DL; Alexander HR; Libutti SK
Cancer Res; 1999 Sep; 59(18):4668-74. PubMed ID: 10493523
[TBL] [Abstract][Full Text] [Related]
20. Ultrastructural aspects of melanization of hamster Ab amelanotic melanoma in primary cell culture.
Bomirski A; Słomiński A
Acta Derm Venereol; 1986; 66(6):520-3. PubMed ID: 2433873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
